A Phase 1 interventional study of Alisertib in Advanced Solid Tumors and Relapsed/Refractory Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-15.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Lymphoma by Takeda — 1 open to participants now, 2 under way, none of them phase 3. Lymphoma · Takeda.
Among the 26 studies in Lymphoma by Takeda, this one is the 12th largest by enrollment of the 23 interventional ones that give a count, is one of 5 that started in 2014, is one of 12 in phase 1, and was the 18th registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →1 of the 26 studies in Lymphoma by Takeda is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in India
Ages 18+
By country, each count listing its studies:
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 6 · Phase 3 2 · Phase 4 3
First in 1997; this study’s year is marked. 5 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 36 across the 23 interventional studies, 1,000 across the 3 observational. Of the 24 that completed or were terminated, 17 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Lymphoma by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of moderate or severe hepatic impairment on the single-dose pharmacokinetics of alisertib in adult participants with cancer.
The drug being tested in this study is called alisertib. Alisertib was tested to assess how it was processed by the body in participants with advanced solid tumors or relapsed/refractory lymphoma with varying degrees of liver function. This study also assessed laboratory results and safety.
The study enrolled 36 participants. Participants were assigned to 1 of the 3 treatment groups based on the status of their liver function: Normal hepatic function (Total bilirubin ≤ upper limit of the normal range [ULN] and alanine aminotransferase [ALT] level ≤ ULN), moderate hepatic impairment (Total bilirubin > 1.5-3 x ULN and ALT level = Any), or severe hepatic impairment (Total bilirubin > 3 x ULN and ALT level = Any). All participants were administered one 50 mg dose of alisertib on Day 1, Cycle 1. Alisertib was administered again on Days 8 through 14 of Cycle 1, followed by a 14-day rest period. Doses administered on Days 8-14 were 50, 30, or 20 mg of alisertib, depending on hepatic function. Alisertib was then continued at the same dose as in Cycle 1, Days 8-14 in 21-day cycles (7 days of alisertib followed by a 14-day rest period) for up to 1 year (approximately 16 cycles).
This multicenter trial was conducted in USA only. The overall time to participate in this study was up to 312 Days. Participants made multiple visits to the clinic including an end-of-study visit 30 days after the last dose of study drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female participants who:
Male participants, even if surgically sterilized (ie, status postvasectomy), who:
Clinical laboratory values as specified below:
(ANC) ≥ 1500/μL and count ≥ 75,000/μL.
Exclusion Criteria:
A medical condition requiring use of pancreatic enzymes; daily, chronic, or regular use of proton pump inhibitors (PPIs); or histamine 2 (H2) receptor antagonists. Participants who intermittently use these medications, must meet the following criteria:
Symptomatic . Participants with brain metastases:
Known history of infection or suspected currently active hepatitis C infection, or known or suspected history of infection. Participants with known or suspected history of hepatitis B infection were to be screened and excluded when any of the following conditions were met:
Any of the following cardiovascular conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alisertib 50 mg, orally, once, on Cycle 1 Day 1, followed by, alisertib 50 mg, orally, twice daily (BID) for 7 days (Cycle 1 Day 8 to 14) followed by a 14-day rest period. Starting at Cycle 2 Day 1, alisertib 50 mg, BID for 7 days, followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months. Normal hepatic function includes participants with total bilirubin ≤ upper limit of the normal range \[ULN\] and alanine aminotransferase \[ALT\] level ≤ ULN.
Drug: Alisertib
Alisertib 50 mg, orally, once, on Cycle 1 Day 1, followed by alisertib 30 mg, BID for 7 days (Cycle 1 Day 8 to 14), followed by a 14-day rest period. Starting at Cycle 2 Day 1, alisertib 30 mg, BID for 7 days followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months. Moderate hepatic impairment includes participants with total bilirubin \> 1.5-3 x ULN and any ALT level.
Drug: Alisertib
Alisertib 50 mg, orally, once, on Cycle 1 Day 1, followed by, alisertib 20 mg, BID for 7 days (Cycle 1 Day 8 to 14) followed by a 14-day rest period. Starting at Cycle 2 Day 1, alisertib 20 mg, BID for 7 days followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months. Severe hepatic impairment includes participants with total bilirubin \> 3 x ULN and any ALT level.
Drug: Alisertib
Alisertib will be supplied as enteric coated tablets.
Also known as: MLN8237
Unbound Cmax: Maximum Observed Plasma Concentration for Alisertib
Time frame: Cycle 1 Day 1 Pre-dose and, and at multiple timepoints (up to 168 hours) post-dose
Unbound AUClast: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib
Time frame: Cycle 1 Day 1 Pre-dose and, and at multiple timepoints (up to 168 hours) post-dose
Unbound AUC0-∞: Area Under the Concentration-Time Curve From Time 0 to Infinity for Alisertib
Time frame: Cycle 1 Day 1 Pre-dose and, and at multiple timepoints (up to 168 hours) post-dose
Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event
An adverse event is any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: Baseline to 30 days after last dose (Up to 312 Days)
Percentage of Participants Who Experienced at Least 1 Serious Adverse Event
A serious adverse event is any untoward medical occurrence or effect that at any dose of a drug results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is medically important due to other reasons than the above mentioned criteria.
Time frame: Baseline to 30 days after last dose (Up to 312 Days)
Percentage of Participants With Clinically Significant Laboratory Values
Laboratory assessments include serum chemistry and hematology. An abnormal laboratory value was assessed as an AE if that value led to discontinuation or delay in treatment, dose modification, therapeutic intervention, or was considered by the investigator to be a clinically significant change from baseline.
Time frame: Baseline to the end of the study (Up to 312 Days)
Percentage of Participants With Clinically Significant Vital Signs
Vital signs include measurements of sitting diastolic and systolic blood pressure, heart rate, and temperature. Any vital signs determined by the investigator to be clinically significant were recorded as AEs.
Time frame: Baseline to the end of the study (Up to 312 days)
Cmax: Maximum Observed Plasma Concentration for Alisertib Metabolites M1 and M2
Time frame: Cycle 1 Day 1 Pre-dose and, and at multiple timepoints (up to 168 hours) post-dose
Tmax: Time of First Occurrence of Cmax for Alisertib Metabolites M1 and M2
Time frame: Cycle 1 Day 1 Pre-dose and, and at multiple timepoints (up to 168 hours) post-dose
AUClast: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib Metabolites M1 and M2
The area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUC0-last) of the alisertib metabolites M1 and M2 was determined from the concentration-time curve of each participant using non-compartmental methods.
Time frame: Cycle 1 Day 1 Pre-dose and, and at multiple timepoints (up to 168 hours) post-dose
Dose-normalized Trough Concentration of Alisertib on Cycle 1 Day 14
A single blood sample will be collected pre-dose on Cycle 1 Day 14. The concentration of alisertib was determined in the plasma sample and dose-normalized.
Time frame: Pre-dose on Day 14 of Cycle 1
Participants took part in the study at 6 investigative sites in the United States from 21 August 2014 to 18 July 2016.
| Milestone | Alisertib: Normal Hepatic Function | Alisertib: Moderate Hepatic Impairment | Alisertib: Severe Hepatic Impairment |
|---|---|---|---|
| Started | 16 | 12 | 8 |
| Completed | 16 | 12 | 8 |
| Not completed | 0 | 0 | 0 |
| nmol/L | Alisertib: Normal Hepatic Function | Alisertib: Moderate Hepatic Impairment | Alisertib: Severe Hepatic Impairment |
|---|---|---|---|
| Unbound Cmax: Maximum Observed Plasma Concentration for Alisertib | 17.3 ± 9.09 | 28.1 ± 7.82 | 18.5 ± 5.80 |
| h*nmol/L | Alisertib: Normal Hepatic Function | Alisertib: Moderate Hepatic Impairment | Alisertib: Severe Hepatic Impairment |
|---|---|---|---|
| Unbound AUClast: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib | 248.5 ± 131.41 | 859.1 ± 387.85 | 735.4 ± 444.61 |
| h*nmol/L | Alisertib: Normal Hepatic Function | Alisertib: Moderate Hepatic Impairment | Alisertib: Severe Hepatic Impairment |
|---|---|---|---|
| Unbound AUC0-∞: Area Under the Concentration-Time Curve From Time 0 to Infinity for Alisertib | 304.3 ± 119.09 | 937.6 ± 428.98 | 778.0 ± 610.51 |
An adverse event is any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event is defined as an adverse event with an onset that occurs after receiving study drug.
| percentage of participants | Alisertib: Normal Hepatic Function | Alisertib: Moderate Hepatic Impairment | Alisertib: Severe Hepatic Impairment |
|---|---|---|---|
| Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event | 100 | 100 | 100 |
A serious adverse event is any untoward medical occurrence or effect that at any dose of a drug results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is medically important due to other reasons than the above mentioned criteria.
| percentage of participants | Alisertib: Normal Hepatic Function | Alisertib: Moderate Hepatic Impairment | Alisertib: Severe Hepatic Impairment |
|---|---|---|---|
| Percentage of Participants Who Experienced at Least 1 Serious Adverse Event | 44 | 67 | 88 |
Laboratory assessments include serum chemistry and hematology. An abnormal laboratory value was assessed as an AE if that value led to discontinuation or delay in treatment, dose modification, therapeutic intervention, or was considered by the investigator to be a clinically significant change from baseline.
| percentage of participants | Alisertib: Normal Hepatic Function | Alisertib: Moderate Hepatic Impairment | Alisertib: Severe Hepatic Impairment |
|---|---|---|---|
| Gamma-glutamyltransferase increased | 13 | 0 | 0 |
| Alanine aminotransferase increased | 0 | 8 | 0 |
| Aspartate aminotransferase increased | 0 | 8 | 0 |
| Blood bilirubin increased | 0 | 8 | 0 |
| Transaminases increased | 0 | 8 | 0 |
| Blood sodium decreased | 6 | 8 | 0 |
| Blood calcium increased | 6 | 0 | 0 |
| Blood phosphorus decreased | 6 | 0 | 0 |
| Platelet count decreased | 6 | 8 | 0 |
| Blood alkaline phosphatase increased | 6 | 8 | 0 |
| Blood creatinine increased | 0 | 8 | 0 |
| Neutrophil count decreased | 0 | 8 | 0 |
| White blood cell count decreased | 0 | 8 | 0 |
Vital signs include measurements of sitting diastolic and systolic blood pressure, heart rate, and temperature. Any vital signs determined by the investigator to be clinically significant were recorded as AEs.
| percentage of participants | Alisertib: Normal Hepatic Function | Alisertib: Moderate Hepatic Impairment | Alisertib: Severe Hepatic Impairment |
|---|---|---|---|
| Pyrexia | 25 | 8 | 38 |
| Sinus tachycardia | 6 | 0 | 0 |
| nmol/L | Alisertib: Normal Hepatic Function | Alisertib: Moderate Hepatic Impairment | Alisertib: Severe Hepatic Impairment |
|---|---|---|---|
| Metabolite M1 | 370.3 ± 282.02 | 1774.0 ± 904.10 | 2001.9 ± 1094.75 |
| Metabolite M2 | 154.6 ± 82.54 | 173.8 ± 54.39 | 207.3 ± 151.60 |
| hours | Alisertib: Normal Hepatic Function | Alisertib: Moderate Hepatic Impairment | Alisertib: Severe Hepatic Impairment |
|---|---|---|---|
| Metabolite M1 | 3.500 (1.88 to 7.92) | 24.000 (1.00 to 48.30) | 24.150 (9.08 to 96.70) |
| Metabolite M2 | 9.000 (5.88 to 49.30) | 24.050 (9.00 to 72.10) | 24.150 (9.08 to 96.70) |
The area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUC0-last) of the alisertib metabolites M1 and M2 was determined from the concentration-time curve of each participant using non-compartmental methods.
| h*nmol/L | Alisertib: Normal Hepatic Function | Alisertib: Moderate Hepatic Impairment | Alisertib: Severe Hepatic Impairment |
|---|---|---|---|
| Metabolite M1 | 8366.3 ± 10790.88 | 159665.0 ± 116960.23 | 196750.0 ± 117472.08 |
| Metabolite M2 | 8923.1 ± 6539.00 | 17326.0 ± 8562.96 | 16987.5 ± 9384.25 |
A single blood sample will be collected pre-dose on Cycle 1 Day 14. The concentration of alisertib was determined in the plasma sample and dose-normalized.
No measurements were reported for this outcome.
Collected over First dose of study drug to 30 days past last dose (Up to 312 Days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alisertib: Normal Hepatic Function | 2/16 (12.5%) | 7/16 (43.8%) | 15/16 (93.8%) |
| Alisertib: Moderate Hepatic Impairment | 3/12 (25%) | 8/12 (66.7%) | 12/12 (100%) |
| Alisertib: Severe Hepatic Impairment | 4/8 (50%) | 7/8 (87.5%) | 8/8 (100%) |
| Event | Alisertib: Normal Hepatic Function | Alisertib: Moderate Hepatic Impairment | Alisertib: Severe Hepatic Impairment |
|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/16 | 2/12 | 3/8 |
| Colorectal adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/16 | 0/12 | 1/8 |
| Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/16 | 0/12 | 1/8 |
| Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/16 | 0/12 | 1/8 |
| StomatitisGastrointestinal disorders | 0/16 | 0/12 | 1/8 |
| PyrexiaGeneral disorders | 2/16 | 0/12 | 1/8 |
| HyperbilirubinaemiaHepatobiliary disorders | 0/16 | 0/12 | 1/8 |
| Hepatic failureHepatobiliary disorders | 0/16 | 0/12 | 1/8 |
| Biliary tract infectionInfections and infestations | 0/16 | 0/12 | 1/8 |
| SepsisInfections and infestations | 0/16 | 0/12 | 1/8 |
| Event | Alisertib: Normal Hepatic Function | Alisertib: Moderate Hepatic Impairment | Alisertib: Severe Hepatic Impairment |
|---|---|---|---|
| NauseaGastrointestinal disorders | 9/16 | 3/12 | 0/8 |
| AscitesGastrointestinal disorders | 0/16 | 6/12 | 1/8 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/16 | 5/12 | 0/8 |
| HyperbilirubinaemiaHepatobiliary disorders | 0/16 | 5/12 | 0/8 |
| DiarrhoeaGastrointestinal disorders | 6/16 | 4/12 | 0/8 |
| FatigueGeneral disorders | 6/16 | 3/12 | 3/8 |
| AlopeciaSkin and subcutaneous tissue disorders | 6/16 | 3/12 | 1/8 |
| VomitingGastrointestinal disorders | 4/16 | 4/12 | 0/8 |
| DehydrationMetabolism and nutrition disorders | 1/16 | 4/12 | 0/8 |
| ConstipationGastrointestinal disorders | 5/16 | 2/12 | 0/8 |
Safety population was defined as all participants who received at least 1 dose of alisertib.
| Age, Continuous(years) | Alisertib: Normal Hepatic Function | Alisertib: Moderate Hepatic Impairment | Alisertib: Severe Hepatic Impairment | Total |
|---|---|---|---|---|
| Mean | 61.2 ± 10.07 | 54.9 ± 9.89 | 54.0 ± 7.05 | 57.5 ± 9.77 |
| Sex: Female, Male(Participants) | Alisertib: Normal Hepatic Function | Alisertib: Moderate Hepatic Impairment | Alisertib: Severe Hepatic Impairment | Total |
|---|---|---|---|---|
| Female | 5 | 7 | 2 | 14 |
| Male | 11 | 5 | 6 | 22 |
| Race/Ethnicity, Customized(Participants) | Alisertib: Normal Hepatic Function | Alisertib: Moderate Hepatic Impairment | Alisertib: Severe Hepatic Impairment | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 | 4 |
| Not Hispanic or Latino | 14 | 11 | 6 | 31 |
| Not Reported | 1 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Alisertib: Normal Hepatic Function | Alisertib: Moderate Hepatic Impairment | Alisertib: Severe Hepatic Impairment | Total |
|---|---|---|---|---|
| White | 14 | 11 | 6 | 31 |
| Black or African American | 2 | 1 | 2 | 5 |
| Region of Enrollment(Participants) | Alisertib: Normal Hepatic Function | Alisertib: Moderate Hepatic Impairment | Alisertib: Severe Hepatic Impairment | Total |
|---|---|---|---|---|
| United States | 16 | 12 | 8 | 36 |
| Height(cm) | Alisertib: Normal Hepatic Function | Alisertib: Moderate Hepatic Impairment | Alisertib: Severe Hepatic Impairment | Total |
|---|---|---|---|---|
| Mean | 172.9 ± 14.62 | 162.9 ± 7.79 | 178.2 ± 8.10 | 170.1 ± 12.66 |
| Weight(kg) | Alisertib: Normal Hepatic Function | Alisertib: Moderate Hepatic Impairment | Alisertib: Severe Hepatic Impairment | Total |
|---|---|---|---|---|
| Mean | 84.6 ± 20.997 | 85.5 ± 33.881 | 85.8 ± 11.847 | 85.2 ± 24.044 |
| Body surface area(m^2) | Alisertib: Normal Hepatic Function | Alisertib: Moderate Hepatic Impairment | Alisertib: Severe Hepatic Impairment | Total |
|---|---|---|---|---|
| Mean | 2.030 ± 0.3073 | 1.897 ± 0.4028 | 2.056 ± 0.1970 | 1.986 ± 0.3292 |
Ran from Aug 2014 to primary completion in Apr 2016, 19 months.
Results were first posted in Nov 2018, 2 years 7 months after primary completion.
Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 61. This study's 19 months is below that.
Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MLN 8237
Millennium Pharmaceuticals, Inc. →